Home > Insider Trading > Filing (0001104659-24-038589)

Filing Details

Accession Number:: 0001104659-24-038589
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-25 21:46:11
Reporting Period:: 2024-03-21

Accepted Time:: 2024-03-25 21:46:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1831828	Vera Therapeutics Inc.	VERA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1720685	Maha Katabi	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Disposition	2024-03-21	32,756	$43.00	3,595,690	No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
Class A Common Stock	Disposition	2024-03-21	21,918	$44.00	3,573,772	No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
Class A Common Stock	Disposition	2024-03-21	12,617	$45.52	3,561,155	No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
Class A Common Stock	Disposition	2024-03-21	13,718	$46.18	3,547,437	No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
Class A Common Stock	Disposition	2024-03-22	413,450	$40.51	3,133,987	No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
Class A Common Stock	Disposition	2024-03-25	340,000	$40.50	2,793,987	No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.
No	4	S	Indirect	By Sofinnova Venture Partners X, L.P.

Footnotes

A portion of the sales reported herein are matchable, for purposes of Section 16(b) of the Exchange Act, with a purchase (the "Purchase") of shares of Class A Common Stock on January 30, 2024 by Sofinnova Venture Partners X, L.P. ("SVP X"), an entity in which Dr. Katabi has a pecuniary interest. As a result, Dr. Katabi is liable for short-swing profits to the extent of her pecuniary interest in the Purchase and such portion of the sales reported herein. Dr. Katabi has agreed with the Issuer to disgorge her short-swing profits attributable to the matching of the Purchase with the sales reported herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The shares are held directly by SVP X. Sofinnova Management X, L.P. ("SM X LP") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. ("SM X LLC") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Such entities and individuals each disclaim beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.06 to $45.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $41.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.50 to $41.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4.